nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SCN8A—forebrain—attention deficit hyperactivity disorder	0.0121	0.0322	CbGeAlD
Procainamide—SCN7A—cardiovascular system—attention deficit hyperactivity disorder	0.0115	0.0306	CbGeAlD
Procainamide—DNMT1—forebrain—attention deficit hyperactivity disorder	0.0104	0.0278	CbGeAlD
Procainamide—SCN1A—forebrain—attention deficit hyperactivity disorder	0.00913	0.0244	CbGeAlD
Procainamide—DNMT1—cardiovascular system—attention deficit hyperactivity disorder	0.0088	0.0235	CbGeAlD
Procainamide—SCN11A—nervous system—attention deficit hyperactivity disorder	0.00865	0.0231	CbGeAlD
Procainamide—SCN2A—forebrain—attention deficit hyperactivity disorder	0.00838	0.0224	CbGeAlD
Procainamide—SCN11A—central nervous system—attention deficit hyperactivity disorder	0.00833	0.0222	CbGeAlD
Procainamide—SCN10A—forebrain—attention deficit hyperactivity disorder	0.00808	0.0216	CbGeAlD
Procainamide—Moclobemide—MAOA—attention deficit hyperactivity disorder	0.0077	0.294	CrCbGaD
Procainamide—SCN3A—forebrain—attention deficit hyperactivity disorder	0.00737	0.0197	CbGeAlD
Procainamide—SCN9A—midbrain—attention deficit hyperactivity disorder	0.00701	0.0187	CbGeAlD
Procainamide—DNMT1—midbrain—attention deficit hyperactivity disorder	0.00687	0.0183	CbGeAlD
Procainamide—SCN11A—brain—attention deficit hyperactivity disorder	0.00661	0.0176	CbGeAlD
Procainamide—SCN8A—nervous system—attention deficit hyperactivity disorder	0.00656	0.0175	CbGeAlD
Procainamide—SCN8A—central nervous system—attention deficit hyperactivity disorder	0.00631	0.0168	CbGeAlD
Procainamide—CHRM2—forebrain—attention deficit hyperactivity disorder	0.00625	0.0167	CbGeAlD
Procainamide—SCN5A—cardiovascular system—attention deficit hyperactivity disorder	0.00621	0.0166	CbGeAlD
Procainamide—SCN8A—cerebellum—attention deficit hyperactivity disorder	0.00617	0.0165	CbGeAlD
Procainamide—SLC22A1—forebrain—attention deficit hyperactivity disorder	0.00614	0.0164	CbGeAlD
Procainamide—SCN1A—midbrain—attention deficit hyperactivity disorder	0.00603	0.0161	CbGeAlD
Procainamide—DNMT1—nervous system—attention deficit hyperactivity disorder	0.00565	0.0151	CbGeAlD
Procainamide—SCN7A—brain—attention deficit hyperactivity disorder	0.00562	0.015	CbGeAlD
Procainamide—ACHE—midbrain—attention deficit hyperactivity disorder	0.00558	0.0149	CbGeAlD
Procainamide—SCN2A—midbrain—attention deficit hyperactivity disorder	0.00553	0.0148	CbGeAlD
Procainamide—Chloroprocaine—SLC6A3—attention deficit hyperactivity disorder	0.0055	0.21	CrCbGaD
Procainamide—DNMT1—central nervous system—attention deficit hyperactivity disorder	0.00544	0.0145	CbGeAlD
Procainamide—DNMT1—cerebellum—attention deficit hyperactivity disorder	0.00532	0.0142	CbGeAlD
Procainamide—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.00529	0.0141	CbGeAlD
Procainamide—Procaine—SLC6A3—attention deficit hyperactivity disorder	0.00525	0.2	CrCbGaD
Procainamide—SCN4A—nervous system—attention deficit hyperactivity disorder	0.00514	0.0137	CbGeAlD
Procainamide—SCN8A—brain—attention deficit hyperactivity disorder	0.00501	0.0134	CbGeAlD
Procainamide—SCN1A—nervous system—attention deficit hyperactivity disorder	0.00496	0.0132	CbGeAlD
Procainamide—SCN4A—central nervous system—attention deficit hyperactivity disorder	0.00495	0.0132	CbGeAlD
Procainamide—SCN3A—midbrain—attention deficit hyperactivity disorder	0.00486	0.013	CbGeAlD
Procainamide—SCN1A—central nervous system—attention deficit hyperactivity disorder	0.00477	0.0127	CbGeAlD
Procainamide—SCN1A—cerebellum—attention deficit hyperactivity disorder	0.00466	0.0124	CbGeAlD
Procainamide—Metoclopramide—DRD3—attention deficit hyperactivity disorder	0.0046	0.175	CrCbGaD
Procainamide—SCN2A—nervous system—attention deficit hyperactivity disorder	0.00455	0.0121	CbGeAlD
Procainamide—SCN9A—brain—attention deficit hyperactivity disorder	0.0044	0.0118	CbGeAlD
Procainamide—SCN10A—nervous system—attention deficit hyperactivity disorder	0.00439	0.0117	CbGeAlD
Procainamide—SCN2A—central nervous system—attention deficit hyperactivity disorder	0.00438	0.0117	CbGeAlD
Procainamide—ACHE—cerebellum—attention deficit hyperactivity disorder	0.00432	0.0115	CbGeAlD
Procainamide—DNMT1—brain—attention deficit hyperactivity disorder	0.00432	0.0115	CbGeAlD
Procainamide—SCN2A—cerebellum—attention deficit hyperactivity disorder	0.00428	0.0114	CbGeAlD
Procainamide—SCN10A—central nervous system—attention deficit hyperactivity disorder	0.00422	0.0113	CbGeAlD
Procainamide—BCHE—forebrain—attention deficit hyperactivity disorder	0.00416	0.0111	CbGeAlD
Procainamide—SCN3A—nervous system—attention deficit hyperactivity disorder	0.004	0.0107	CbGeAlD
Procainamide—SCN5A—nervous system—attention deficit hyperactivity disorder	0.00399	0.0106	CbGeAlD
Procainamide—SCN4A—brain—attention deficit hyperactivity disorder	0.00393	0.0105	CbGeAlD
Procainamide—SCN3A—central nervous system—attention deficit hyperactivity disorder	0.00385	0.0103	CbGeAlD
Procainamide—SCN5A—central nervous system—attention deficit hyperactivity disorder	0.00384	0.0102	CbGeAlD
Procainamide—SCN1A—brain—attention deficit hyperactivity disorder	0.00379	0.0101	CbGeAlD
Procainamide—SCN3A—cerebellum—attention deficit hyperactivity disorder	0.00376	0.01	CbGeAlD
Procainamide—BCHE—cardiovascular system—attention deficit hyperactivity disorder	0.00351	0.00938	CbGeAlD
Procainamide—ACHE—brain—attention deficit hyperactivity disorder	0.00351	0.00936	CbGeAlD
Procainamide—SCN2A—brain—attention deficit hyperactivity disorder	0.00348	0.00928	CbGeAlD
Procainamide—CHRM2—nervous system—attention deficit hyperactivity disorder	0.00339	0.00906	CbGeAlD
Procainamide—SCN10A—brain—attention deficit hyperactivity disorder	0.00335	0.00895	CbGeAlD
Procainamide—SLC22A1—nervous system—attention deficit hyperactivity disorder	0.00333	0.00889	CbGeAlD
Procainamide—SLC22A4—cerebellum—attention deficit hyperactivity disorder	0.00329	0.00879	CbGeAlD
Procainamide—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.00327	0.00872	CbGeAlD
Procainamide—SLC22A1—central nervous system—attention deficit hyperactivity disorder	0.00321	0.00856	CbGeAlD
Procainamide—SLC22A3—nervous system—attention deficit hyperactivity disorder	0.00319	0.0085	CbGeAlD
Procainamide—Metoclopramide—DRD2—attention deficit hyperactivity disorder	0.00318	0.121	CrCbGaD
Procainamide—SLC22A3—central nervous system—attention deficit hyperactivity disorder	0.00307	0.00818	CbGeAlD
Procainamide—SCN3A—brain—attention deficit hyperactivity disorder	0.00306	0.00815	CbGeAlD
Procainamide—SCN5A—brain—attention deficit hyperactivity disorder	0.00305	0.00813	CbGeAlD
Procainamide—SLC22A5—midbrain—attention deficit hyperactivity disorder	0.00282	0.00752	CbGeAlD
Procainamide—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00275	0.00735	CbGeAlD
Procainamide—BCHE—midbrain—attention deficit hyperactivity disorder	0.00274	0.00732	CbGeAlD
Procainamide—SLC22A4—brain—attention deficit hyperactivity disorder	0.00268	0.00714	CbGeAlD
Procainamide—CHRM2—brain—attention deficit hyperactivity disorder	0.00259	0.00692	CbGeAlD
Procainamide—SLC22A1—brain—attention deficit hyperactivity disorder	0.00255	0.0068	CbGeAlD
Procainamide—SLC22A3—brain—attention deficit hyperactivity disorder	0.00244	0.0065	CbGeAlD
Procainamide—BCHE—nervous system—attention deficit hyperactivity disorder	0.00226	0.00602	CbGeAlD
Procainamide—SLC22A5—cerebellum—attention deficit hyperactivity disorder	0.00218	0.00582	CbGeAlD
Procainamide—BCHE—central nervous system—attention deficit hyperactivity disorder	0.00217	0.0058	CbGeAlD
Procainamide—BCHE—cerebellum—attention deficit hyperactivity disorder	0.00212	0.00567	CbGeAlD
Procainamide—SLC22A5—brain—attention deficit hyperactivity disorder	0.00177	0.00472	CbGeAlD
Procainamide—BCHE—brain—attention deficit hyperactivity disorder	0.00172	0.0046	CbGeAlD
Procainamide—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00149	0.00399	CbGeAlD
Procainamide—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00144	0.00384	CbGeAlD
Procainamide—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.00141	0.00375	CbGeAlD
Procainamide—CYP2D6—brain—attention deficit hyperactivity disorder	0.00114	0.00305	CbGeAlD
Procainamide—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000989	0.00165	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000976	0.00163	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.000964	0.00161	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000958	0.0016	CbGpPWpGaD
Procainamide—SLC22A4—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.00095	0.00159	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000944	0.00158	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.000936	0.00156	CbGpPWpGaD
Procainamide—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000922	0.00154	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00092	0.00154	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.00092	0.00154	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000916	0.00153	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000911	0.00152	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000887	0.00148	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000887	0.00148	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—ANK3—attention deficit hyperactivity disorder	0.000885	0.00148	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000876	0.00146	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—CACNB2—attention deficit hyperactivity disorder	0.000874	0.00146	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000871	0.00145	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000845	0.00141	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000842	0.00141	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000842	0.00141	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.00084	0.0014	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000812	0.00136	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000812	0.00136	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000809	0.00135	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—CACNA1C—attention deficit hyperactivity disorder	0.0008	0.00133	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000784	0.00131	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000781	0.0013	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000778	0.0013	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000769	0.00128	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000768	0.00128	CbGpPWpGaD
Procainamide—CHRM2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.000768	0.00128	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000762	0.00127	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—POLR3A—attention deficit hyperactivity disorder	0.000752	0.00126	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000749	0.00125	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000748	0.00125	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000725	0.00121	CbGpPWpGaD
Procainamide—SLC22A3—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000716	0.0012	CbGpPWpGaD
Procainamide—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000714	0.00119	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000696	0.00116	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000696	0.00116	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000696	0.00116	CbGpPWpGaD
Procainamide—ACHE—ATF-2 transcription factor network—EP300—attention deficit hyperactivity disorder	0.000674	0.00112	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000672	0.00112	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000669	0.00112	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000667	0.00111	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000658	0.0011	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000656	0.0011	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—SLC6A4—attention deficit hyperactivity disorder	0.000647	0.00108	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000647	0.00108	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000643	0.00107	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000626	0.00105	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000624	0.00104	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000624	0.00104	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000622	0.00104	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000621	0.00104	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000612	0.00102	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.000611	0.00102	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000598	0.000998	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000596	0.000995	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000592	0.000988	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000588	0.000982	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000587	0.000981	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000584	0.000974	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00058	0.000968	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000574	0.000958	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000574	0.000958	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000571	0.000953	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000556	0.000928	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000554	0.000925	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000534	0.000891	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000533	0.00089	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000532	0.000889	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000528	0.000881	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000524	0.000875	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000517	0.000863	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000513	0.000856	CbGpPWpGaD
Procainamide—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000512	0.000854	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000511	0.000854	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000501	0.000837	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000501	0.000836	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000487	0.000813	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000483	0.000806	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000478	0.000798	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000477	0.000796	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000476	0.000794	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000471	0.000787	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.00047	0.000784	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000468	0.000781	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000465	0.000777	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000456	0.000761	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000453	0.000757	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000451	0.000754	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.00045	0.000751	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000449	0.00075	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000444	0.000742	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000444	0.000741	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000439	0.000733	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000438	0.000732	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000436	0.000728	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000433	0.000722	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000431	0.000719	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000425	0.000709	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000419	0.000699	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000419	0.000699	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000412	0.000687	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000408	0.000682	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000408	0.000681	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000407	0.000679	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000404	0.000675	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000401	0.00067	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000399	0.000666	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000397	0.000663	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.000396	0.000661	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000395	0.000659	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000391	0.000653	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000379	0.000632	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000371	0.000619	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000364	0.000608	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000363	0.000606	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000361	0.000603	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000359	0.000599	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000359	0.000599	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000353	0.000589	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000352	0.000587	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000348	0.000582	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000347	0.00058	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000347	0.000579	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000337	0.000562	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000334	0.000558	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000325	0.000542	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000322	0.000537	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000304	0.000507	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000289	0.000483	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000283	0.000473	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000282	0.000471	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000274	0.000457	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000273	0.000456	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000273	0.000456	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000272	0.000454	CbGpPWpGaD
Procainamide—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00027	0.000451	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000269	0.000449	CbGpPWpGaD
Procainamide—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000265	0.000443	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000265	0.000443	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000263	0.000439	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000262	0.000438	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.00026	0.000434	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000257	0.000429	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000249	0.000416	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000247	0.000413	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000243	0.000407	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000239	0.0004	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000239	0.0004	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000239	0.000399	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000239	0.000399	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000235	0.000393	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000231	0.000386	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000231	0.000385	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000231	0.000385	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000228	0.000381	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000227	0.00038	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000219	0.000365	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000217	0.000363	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000213	0.000355	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.00021	0.000351	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000203	0.000338	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000196	0.000328	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000191	0.000319	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000188	0.000315	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000188	0.000315	CbGpPWpGaD
Procainamide—ACHE—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000185	0.000309	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000182	0.000304	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00018	0.000301	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000178	0.000298	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000173	0.000289	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000172	0.000288	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000172	0.000286	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000168	0.000281	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000168	0.000281	CbGpPWpGaD
Procainamide—BCHE—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000165	0.000276	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000162	0.000271	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000159	0.000266	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000156	0.00026	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000155	0.000259	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000154	0.000258	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000154	0.000257	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000152	0.000254	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000152	0.000253	CbGpPWpGaD
Procainamide—ACHE—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000151	0.000251	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00015	0.000251	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00015	0.000251	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00015	0.00025	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000149	0.000249	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000148	0.000247	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000145	0.000242	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000145	0.000242	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000144	0.00024	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000143	0.000239	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00014	0.000234	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00014	0.000234	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00014	0.000234	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00014	0.000233	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000138	0.00023	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000138	0.00023	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000137	0.000229	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000136	0.000227	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000134	0.000224	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000128	0.000214	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000128	0.000214	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000127	0.000212	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00012	0.0002	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000114	0.000191	CbGpPWpGaD
Procainamide—ACHE—Metabolism—COMT—attention deficit hyperactivity disorder	0.000114	0.000191	CbGpPWpGaD
Procainamide—ACHE—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000113	0.000189	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000112	0.000187	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000112	0.000187	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00011	0.000183	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000106	0.000178	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000105	0.000176	CbGpPWpGaD
Procainamide—BCHE—Metabolism—COMT—attention deficit hyperactivity disorder	0.000102	0.00017	CbGpPWpGaD
Procainamide—BCHE—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000101	0.000169	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	9.8e-05	0.000164	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.78e-05	0.000163	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.2e-05	0.000154	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—COMT—attention deficit hyperactivity disorder	9.09e-05	0.000152	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—MAOA—attention deficit hyperactivity disorder	9.03e-05	0.000151	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.88e-05	0.000148	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.56e-05	0.000143	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—COMT—attention deficit hyperactivity disorder	8.48e-05	0.000142	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—MAOA—attention deficit hyperactivity disorder	8.42e-05	0.000141	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.29e-05	0.000138	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.14e-05	0.000136	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.04e-05	0.000134	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	7.73e-05	0.000129	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.73e-05	0.000129	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	7.6e-05	0.000127	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.49e-05	0.000125	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.07e-05	0.000118	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—EP300—attention deficit hyperactivity disorder	6.22e-05	0.000104	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.18e-05	0.000103	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.88e-05	9.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.25e-05	8.76e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—EP300—attention deficit hyperactivity disorder	4.89e-05	8.17e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	4.68e-05	7.82e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	4.65e-05	7.76e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—EP300—attention deficit hyperactivity disorder	4.37e-05	7.29e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—EP300—attention deficit hyperactivity disorder	3.9e-05	6.51e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—EP300—attention deficit hyperactivity disorder	3.63e-05	6.07e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.78e-05	4.64e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	2.01e-05	3.35e-05	CbGpPWpGaD
